Aptar Pharma, a company involved in drug delivery systems, services, and active material science solutions, opened its new Aptar Mumbai site, increasing manufacturing capabilities in Southeast Asia.

Manufacturing capabilities at Aptar Mumbai, which began in 2012 with the assembly and supply of metered dose valves and pumps, have now been expanded to offer more innovative product solutions and ensure increased manufacturing capacity for pharma customers in Southeast Asia.

Assembly operations and product delivery to customers have already begun at the new 7,000 m² state-of-the art site, which has also received ISO 15378 certification.

The expansion, which began in early 2022, is in line with Aptar’s localization strategy, and is a direct response to growing customer demand in the region.

“Our Aptar Pharma business in India has shown robust growth in recent years, and today marks yet another milestone in our investment in the Southeast Asia region,” said Gael Touya, president, Aptar Pharma. “Over the past 11 years, Aptar Mumbai has continuously supplied safe, high-quality products that meet even the highest of regulatory requirements. This new facility is a key step in serving the needs of our customers in the region, which will ultimately benefit patients.”